Article Text

Download PDFPDF

1261 Increased concentrations of S100B and neurofilament light chain in serum indicate checkpoint inhibitor-induced CNS inflammation
  1. Sara Bjursten1,
  2. Ankur Pandita1,
  3. Zhiyuan Zhao1,
  4. Joel Simrén2,
  5. Henrik Zetterberg2,
  6. Anna Rudin3,
  7. Lars Ny1 and
  8. Max Levin1
  1. 1Sahlgrenska University Hospital, Gothenburg, Sweden
  2. 2Institute of Neuroscience and Physiology, Gothenburg, Sweden
  3. 3Institute of Medicine, Sahlgrenska, Gothenburg, Sweden


Background Checkpoint inhibitor (CPI)-induced CNS inflammation is a severe neurological adverse event.1, 2 CPI-induced CNS inflammation can be difficult to diagnose because symptoms indicate more common conditions such as tumor progression or infection.3-5 There is a clinical need for blood tests to facilitate diagnosis of CPI-induced CNS inflammation.

Our objective was to evaluate if increased concentrations of brain damage markers S-calcium-binding protein B (S100B) and neurofilament light chain (NfL) in serum indicate CPI-induced CNS inflammation.

Methods Medical records and laboratory data were examined in patients with metastatic melanoma or metastatic renal cell carcinoma. The patients were treated with double checkpoint inhibition (nivolumab and ipilimumab) between March 2018 and April 2022 (n=197) at Sahlgrenska University Hospital, Sweden. In patients with suspected CNS-inflammation, brain MRI and analysis of cerebrospinal fluid were performed and brain damage markers S100B and NfL in serum were analyzed repeatedly. S-100B has a dual function as it is secreted by some melanoma metastases as well as damaged astrocytes.6, 7 S-100B concentrations in patients with melanoma metastases that do not secrete S-100B (n=29) and renal cell carcinoma patients (n=10) were used as double checkpoint inhibitor treated controls. As controls for NfL, we analyzed frozen plasma from melanoma patients treated with double checkpoint inhibition (ipilimumab + nivolumab) or monotherapy nivolumab (n=49).

Results Nine out of 197 patients had a verified CPI-induced CNS inflammation (4.6%) within 200 days from the first double checkpoint inhibitor treatment (table 1). S100B and NfL in serum increased during CNS inflammation (figure 1A-D and F) and normalized when patients were treated with immunosuppression (figure 1A-C, E and G). S100B concentration in serum increased early in patients with CPI-induced CNS inflammation (figure 1A-C), whereas NfL increased later (figure 1A-C). The sensitivity of an increased S100B and NfL to detect a CPI-induced CNS inflammation was 100% for S100B and 79% for NfL and the specificity was 89% for S100B and 74% for NfL (figure 2).

Conclusions The combined analysis of S100B and NfL in serum is a tool for early detection and monitoring of CPI-induced CNS inflammation. Early diagnosis of CPI-induced CNS inflammation may save lives, prevent long-term hospitalization, and reduce neurological complications.


  1. D Dubey et al. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Ann Neurol. 2020;87(5):659669. doi: 10.1002/ana.25708.

  2. S Bjursten et al. Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis. J Immunother Cancer. 2021;9(7). doi: 10.1136/jitc-2021-002732.

  3. JR Brahmer et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–1768. doi: 10.1200/JCO.2017.77.6385.

  4. J Haanen et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv264–iv266. doi: 10.1093/annonc/mdy162.

  5. I Puzanov et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1)95. doi: 10.1186/s40425-017-0300-z.

  6. HD Abraha, LC Fuller, AWPDU Vivier, EM Higgins, and RA Sherwood. Serum S100 protein: a potentially useful prognostic marker in cutaneous melanoma. British Journal of Dermatology. 1997;137:381-385.

  7. R Gerlach et al. Active secretion of S100B from astrocytes during metabolic stress. Neuroscience. 2006;141(4):1697–701. doi: 10.1016/j.neuroscience.2006.05.008.

Ethics Approval The study was approved by the Regional Ethics Board (151-16, 477-18, 2021-04093)

Abstract 1261 Table 1

Checkpoint inhibitor-induced CNS inflammation

Abstract 1261 Figure 1

Neurological Symptoms and Serum Concentrations of Brain Damage Marker S100B and NfL in Patients with or without CPI-induced CNS inflammation

Abstract 1261 Figure 2

Receiver-Operating Characteristic (ROC) Curves

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.